肺炎链球菌
利奈唑啉
医学
荟萃分析
微生物学
病毒学
生物
内科学
抗生素
细菌
遗传学
金黄色葡萄球菌
万古霉素
作者
Mohsen Heidary,Shirin Dashtbin,Arezoo Asadi,Parisa Asadollahi,Ali Khatib,Mohammad Amin Ebrahimi,Zahra Ghanbari,Atieh Darbandi,Roya Ghanavati,Reza Pakzad
标识
DOI:10.2217/fmb-2023-0170
摘要
Aim: This study aimed to understand the current level of linezolid (LNZ) resistance in Streptococcus pneumoniae isolates reported over the past 10 years. Material & methods: An electronic search was conducted for the following keywords: ((Streptococcus pneumoniae [title/abstract]) OR (Pneumococcus [title/abstract]) OR (Pneumococci [title/abstract]) AND (linezolid [title/abstract]) OR (Zyvox [title/abstract])) OR (Zyvoxid [title/abstract])). Result: Out of all the studies, 80 had a cross-sectional design, while 11 followed a cohort approach. The prevalence of LNZ resistance among S. pneumoniae isolates ranged from 0% to 4.86%. Discussion: Urgent, high-powered, randomized, controlled trials with participants from endemic regions are needed to gain a comprehensive understanding of the impact on and significance of LNZ treatment to patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI